Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Ann Surg Oncol ; 2022 Mar 23.
Artículo en Inglés | MEDLINE | ID: mdl-35320428

RESUMEN

BACKGROUND: The expression of liver kinase B1 (LKB-1) has been associated with prognosis in squamous cell carcinoma of the oral cavity (SCCOC). This study aimed to define the prognostic role of LKB-1 expression for patients with SCCOC and the suitability of its integration into a multivariate prognostic model. METHODS: A retrospective cohort study of patients with SCCOC was conducted in a cancer center. Expression of LKB-1 was evaluated by immunohistochemistry, and multivariate analysis defined prognostic factors associated with recurrence, recurrence-free survival (RFS), and overall survival (OS). The logistic regression model was used to construct a predictive computer software program. RESULTS: Of the 201 patients in this study, 104 (51.7%) experienced recurrence of their disease. Lower expression of LKB-1, high-risk histopathology, and advanced tumor-node-metastasis (TNM) stages were independent factors via multivariate analysis associated with the increased recurrence risk, poor RFS, and poor OS. If lack of LKB-1 expression is considered the reference category, the factors independently associated with recurrence were low (odds ratio [OR], 0.157; 95% confidence interval [CI], 0.044-0.557), intermediate (OR, 0.073; 95% CI, 0.017-0.319), and intense (OR, 0.047; 95% CI, 0.007-0.304) expression of LKB-1. This model permitted construction of a computer software program capable of prediction with receiver operating characteristic analysis (area under the curve, 0.925) and led to the definition of five prognostic groups with a biologic gradient. CONCLUSION: These results suggest that LKB-1 expression in patients with SCCOC is of robust prognostic value and complements the TNM staging system. The proposed model requires external validation in prospective observational studies.

2.
Oncology (Williston Park) ; 34(6): 211-215, 2020 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-32609868

RESUMEN

LP strategies should be considered only in patients with resectable stage III/IV larynx and hypopharynx SCC, ideally those who have a functional larynx. The choice of treatment must be discussed by a multidisciplinary team, and the patient must have an active role in making the decision. CRT and IC-RT are both approved larynx-preservation approaches. IC-RT has demonstrated high rates of LP without decreasing DFS or OS, compared with surgery. CRT has demonstrated better LP rates, as well as local control and LRC, compared with IC-RT, and it should be considered a standard of care.


Asunto(s)
Neoplasias Hipofaríngeas/terapia , Tratamientos Conservadores del Órgano/métodos , Carcinoma de Células Escamosas de Cabeza y Cuello/terapia , Quimioradioterapia , Humanos , Neoplasias Hipofaríngeas/patología , Quimioterapia de Inducción , Comunicación Interdisciplinaria , Laringectomía/métodos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Carcinoma de Células Escamosas de Cabeza y Cuello/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA